アジア太平洋の運動失調症市場 – 業界動向と2029年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

アジア太平洋の運動失調症市場 – 業界動向と2029年までの予測

  • Pharmaceutical
  • Published Report
  • Apr 2022
  • Asia-Pacific
  • 350 ページ
  • テーブル数: 363
  • 図の数: 48

>アジア太平洋地域の運動失調症市場、タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療と診断)、剤形別(固形、液体、その他)、投与経路別(経口、非経口、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他) - 2029年までの業界動向と予測。

アジア太平洋の運動失調症市場

アジア太平洋市場の分析と洞察 

運動失調症の罹患率の増加により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。この重要な時期に、主要な市場プレーヤーは製品の発売と承認に非常に注力しています。さらに、政府と規制当局は、急増する新興疾患に対する製品承認によって市場プレーヤーをサポートしています。

アジア太平洋の運動失調症市場

アジア太平洋の運動失調症市場

アジア太平洋の運動失調症市場は、市場プレーヤーの増加と高度な製品の利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場に新しい製品を投入するための研究開発活動に取り組んでいます。運動失調症治療の分野での研究の増加と、アルコール消費と薬物使用の増加により、市場の成長がさらに促進されると予想されます。ただし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設が不足しているため、予測期間中のアジア太平洋の運動失調症市場の成長が妨げられる可能性があります。

医療費の増加と市場プレーヤーによる戦略的取り組みにより、市場には治療を強化する機会がもたらされる可能性があります。ただし、医薬品や製品の承認に関連する厳格な規則や規制、さまざまな企業による製品リコールが、市場の成長を妨げると予想されます。

アジア太平洋地域の運動失調症市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に7.8%のCAGRで成長し、2021年の4,443.95千米ドルから2029年には7,734.86千米ドルに達すると分析しています。

レポートメトリック

詳細

予測期間

2022年から2029年

基準年

2021

歴史的な年

2020

定量単位

収益は1000米ドル、価格は米ドル

対象セグメント

タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療および診断)、剤形別(固形剤、液体剤、その他)、投与経路別(経口剤、非経口剤、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他)

対象国

中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋諸国

対象となる市場プレーヤー

Novartis AG、Merck KGaA、Aurobindo Pharma、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Viatris Inc.、Sun Pharmaceutical Industries Ltd.、Lupin、Amneal Pharmaceuticals LLC.、Apotex Inc.、Cipla Inc.、Reata Pharmaceuticals, Inc.、Biohaven Pharmaceuticals など

市場の定義

運動失調症は、協調運動、バランス、発話に影響を及ぼす一連の障害を指す用語です。どの部位にも影響が出る可能性がありますが、運動失調症の人はバランス、歩行、発話、嚥下、および書くこと、食べること、視覚など高度な制御を必要とする作業に困難を抱えることがよくあります。正確な症状とその重症度は、患者の運動失調症の種類によって異なります。

運動失調症は通常、脳の小脳と呼ばれる部分の損傷によって起こりますが、神経系の他の部分の損傷によっても起こることがあります。この損傷は、MS (多発性硬化症) などの基礎疾患の一部である場合もあれば、頭部外傷、脳への酸素不足、長期にわたる過度のアルコール摂取によって起こる場合もあります。遺伝性運動失調症は、影響を受けるかどうかは不明ですが、家族から受け継がれた欠陥遺伝子によって引き起こされます。

アジア太平洋の運動失調症市場の動向

ドライバー

  • 運動失調症の有病率と発症率の増加

運動失調症は、運動と協調性に影響を与える神経系に関連する神経疾患の用語です。運動失調症の人は、バランス、協調性、嚥下、発話に問題を抱えることがよくあります。運動失調症は通常、運動を調整する小脳である脳の一部が損傷することで発症します。これはまれな病気ですが、その発症は世界中で非常に蔓延しています。この病気は世界中で大きな臨床問題として広く認識されており、罹患率と死亡率の負担が大きくなっています。したがって、さまざまな年齢層に影響を与える運動失調症の有病率と発症率の増加が、アジア太平洋地域の運動失調症市場を牽引しています。

  • 運動失調症治療の分野における急速な研究

運動失調症には、非常に多くの危険因子が報告されています。したがって、運動失調症に関連する危険因子と症状を軽減するために、運動失調症治療の分野でさまざまな研究が行われています。市場におけるさまざまな種類の運動失調症を治療するために、政府による資金援助も開始されています。運動失調症治療の分野でのさまざまな急速な研究は、予測期間中に市場を牽引し、同治療の研究開発の大幅な成長を予測するのに役立ちます。

機会

  • 医療費の増大

各国の人々の可処分所得が増加しているため、医療費は世界中で増加しています。さらに、人口の要件を満たすために、政府機関と医療機関は医療費の加速化によって主導権を握っています。医療費の増加は、同時に、近年この疾患が非常に蔓延しているため、医療現場が運動失調症の治療施設を改善するのにも役立ちます。

また、主要な市場プレーヤーが講じる戦略的取り組みは、2022~2029年の予測期間において、運動失調症市場に構造的完全性と将来の機会をもたらすでしょう。

制約/課題

しかし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設も不足しているため、運動失調症市場の成長率は低下するでしょう。さらに、厳しい規則や規制が予測期間の市場にさらなる課題をもたらすでしょう。

このアジア太平洋の運動失調症市場レポートでは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。アジア太平洋の運動失調症市場に関する詳細情報を取得するには、アナリスト ブリーフについて Data Bridge Market Research にお問い合わせください。当社のチームが、市場の成長を達成するための情報に基づいた市場決定を行うお手伝いをいたします。

COVID-19後のアジア太平洋の運動失調症市場への影響

COVID-19は市場にプラスの影響を与えています。パンデミック中のロックダウンと隔離は、病気の管理と服薬遵守を複雑にします。そのため、さまざまな治療薬が世界の人口に広く増加しています。したがって、パンデミックはこの市場にプラスの影響を与えています。

最近の開発

  • 2022年11月、ファイザー社はアリーナ・ファーマシューティカルズの買収を完了したことを発表しました。同社は、いくつかの免疫炎症性疾患を治療するための革新的な潜在的治療法を開発している臨床段階の企業です。この買収により、同社は製品ポートフォリオを拡大することができました。

アジア太平洋の運動失調症市場の範囲

アジア太平洋の運動失調症市場は、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネルに分類されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。

タイプ

  • 脊髄小脳失調症
  • 毛細血管拡張性運動失調症
  • 発作性運動失調症
  • その他(多系統萎縮症(MSA))

タイプに基づいて、アジア太平洋地域の運動失調症市場は、脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA))に分類されます。

製品

  • 診断
  • 処理

製品に基づいて、アジア太平洋の運動失調症市場は治療と診断に分類されます。

剤形

  • 固体
  • 液体
  • その他

剤形に基づいて、アジア太平洋地域の運動失調市場は、固体、液体、その他に分類されます。

投与経路

  • オーラル     
  • 非経口
  • その他

投与経路に基づいて、アジア太平洋地域の運動失調症市場は、経口、非経口、その他に分類されます。

患者タイプ

  • アダルト
  • 子供
  • 老年病

患者のタイプに基づいて、アジア太平洋地域の運動失調症市場は、成人、小児、高齢者に分類されます。

エンドユーザー

  • 病院
  • クリニック
  • 在宅医療
  • その他

エンドユーザーに基づいて、アジア太平洋地域の運動失調症市場は、病院、診療所、在宅医療、その他に分類されます。

流通チャネル

  • 直接入札
  • 小売販売
  • その他

アジア太平洋の運動失調症市場

流通チャネルに基づいて、アジア太平洋の運動失調症市場は、直接入札、小売販売、その他に分類されます。

アジア太平洋の運動失調症市場の地域分析/洞察

アジア太平洋地域の運動失調症市場が分析され、国、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネル別に市場規模の洞察と傾向が提供されます。

この地域に含まれる国には、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋諸国があります。中国は、市場シェアと市場収益の面でアジア太平洋の運動失調症市場を支配すると予想されており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域での運動失調症の有病率が高いためであり、急速な研究開発が市場を後押ししています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。

競争環境とアジア太平洋の運動失調症市場シェア分析

アジア太平洋の運動失調症市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、アジア太平洋の運動失調症市場に対する会社の重点にのみ関連しています。

アジア太平洋地域の運動失調症市場で活動している主要企業としては、ノバルティス AG、メルク KGaA、オーロビンド ファーマ、ファイザー社、サノフィ、テバ製薬工業株式会社、ビアトリス社、サン製薬工業株式会社、ルピン社、アムニール製薬株式会社、アポテックス社、シプラ社、リアタ製薬株式会社、バイオヘイブン製薬などが挙げられます。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、アジア太平洋と地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC ATAXIA MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 ASIA PACIFIC ATAXIA MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA

7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS

7.1.3 RISE IN ALCOHOL AND DRUG USAGE

7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE

7.2 RESTRAINTS

7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE

7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES

7.3 OPPORTUNITIES

7.3.1 RISING HEALTHCARE EXPENDITURE

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.4 CHALLENGES

7.4.1 STRINGENT RULES AND REGULATIONS

7.4.2 PRODUCT RECALL

8 ASIA PACIFIC ATAXIA MARKET, BY TYPE

8.1 OVERVIEW

8.2 SPINOCEREBELLAR ATAXIAS

8.2.1 TYPE 3

8.2.2 TYPE 2

8.2.3 TYPE 1

8.2.4 OTHERS

8.3 ATAXIA-TELANGIECTASIA

8.4 EPISODIC ATAXIA

8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))

9 ASIA PACIFIC ATAXIA MARKET, BY PRODUCT

9.1 OVERVIEW

9.2 TREATMENT

9.2.1 PHARMACOTHERAPY

9.2.1.1 STIFFNESS/SPASTICITY

9.2.1.1.1 GABAPENTIN

9.2.1.1.2 LEVODOPA

9.2.1.1.3 OTHERS

9.2.1.2 GAIT AND TREMORS

9.2.1.2.1 VARENICLINE

9.2.1.2.2 RILUZOLE

9.2.1.2.3 AMANTADINE

9.2.1.2.4 OTHERS

9.2.1.3 ANTI-OXIDANTS

9.2.1.3.1 N‐ACETYLCYSTEINE

9.2.1.3.2 SELEGILINE

9.2.1.3.3 DEHYDROEPIANDROSTERONE

9.2.1.3.4 VITAMIN E

9.2.1.4 NON ANTI-OXIDANTS

9.2.1.4.1 ERYTHROPOIETIN

9.2.1.4.2 DEFERIPRONE

9.2.1.4.3 RESVERATROL

9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS

9.2.1.5 ANTI-ARRHYTHMIC AGENTS

9.2.1.5.1 AMIODARONE

9.2.1.5.2 PROPAFENONE

9.2.1.5.3 FLECAINIDE

9.2.1.5.4 IBUTILIDE

9.2.1.6 ANTI-CARDIAC FAILURE

9.2.1.6.1 BENAZEPRIL

9.2.1.6.2 LISINOPRIL

9.2.1.6.3 CAPTOPRIL

9.2.1.6.4 ENALAPRIL

9.2.1.6.5 FOSINOPRIL

9.2.1.6.6 MOEXIPRIL

9.2.1.6.7 OTHERS

9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS

9.2.1.7.1 BIGUANIDES (METFORMIN)

9.2.1.7.2 SULFONYLUREAS

9.2.1.7.2.1 GLIPIZIDE

9.2.1.7.2.2 GLIMEPIRIDE

9.2.1.7.2.3 GLYBURIDE

9.2.1.7.2.4 OTHERS

9.2.1.7.3 THIAZOLIDINEDIONES

9.2.1.7.4 MEGLITINIDES

9.2.2 LIFESTYLE THERAPY

9.2.2.1 PHYSICAL THERAPY

9.2.2.2 SPEECH THERAPY

9.2.2.3 PALLIATIVE CARE

9.2.2.4 OTHERS

9.2.3 SUPPORTIVE DEVICES

9.2.3.1 WALKING AIDS

9.2.3.2 WHEELCHAIRS

9.2.3.3 OTHERS

9.3 DIAGNOSTICS

9.3.1 IMAGING TEST

9.3.1.1 MRI SCAN

9.3.1.2 OTHERS

9.3.2 BLOOD TEST

9.3.3 GENETIC TESTING

10 ASIA PACIFIC ATAXIA MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 SOLID

10.2.1 TABLETS

10.2.2 CAPSULES

10.2.3 OTHERS

10.3 LIQUIDS

10.3.1 INJECTION

10.3.2 SOLUTIONS

10.3.3 OTHERS

10.4 OTHERS

11 ASIA PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.4 OTHERS

12 ASIA PACIFIC ATAXIA MARKET, BY PATIENT TYPE

12.1 OVERVIEW

12.2 ADULT

12.2.1 MALE

12.2.2 FEMALE

12.3 CHILD

12.4 GERIATRIC

13 ASIA PACIFIC ATAXIA MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 ASIA PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDER

14.3 RETAIL SALES

14.3.1 HOSPITAL PHARMACY

14.3.2 RETAIL SHOP

14.3.3 ONLINE PHARMACY

14.4 OTHERS

15 ASIA PACIFIC ATAXIA MARKET, BY GEOGRAPHY

15.1 ASIA-PACIFIC

15.1.1 CHINA

15.1.2 JAPAN

15.1.3 INDIA

15.1.4 SOUTH KOREA

15.1.5 AUSTRALIA

15.1.6 SINGAPORE

15.1.7 THAILAND

15.1.8 MALAYSIA

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 RESTF OF ASIA-PACIFIC

16 ASIA PACIFIC ATAXIA MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 SELECT MEDICAL CORPORATION

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 PFIZER INC.

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 NOVARTIS AG

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 AMNEAL PHARMACEUTICALS LLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLI

18.4.5 RECENT DEVELOPMENT

18.5 UPSTREAM REHABILITATION INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 COMPANY SHARE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 PRIORY

18.6.1 COMPANY SNAPSHOT

18.6.2 COMPANY SHARE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 ACORDA THERAPEUTICS, INC.

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 ADVERUM BIOTECHNOLOGIES, INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 APOTEX INC.

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENT

18.1 ATI PHYSICAL THERAPY

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 AUROBINDO PHARMA

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 BANNER HEALTH

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENT

18.13 BIOHAVEN PHARMACEUTICALS

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 BIOVISTA

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 CIPLA INC.

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 DESIGN THERAPEUTICS, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 INTRABIO

18.17.1 COMPANY SNAPSHOT

18.17.2 PRODUCT PORTFOLIO

18.17.3 RECENT DEVELOPMENT

18.18 LUPIN.

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENTS

18.19 MATRIX BIOMED

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 MERCK KGAA

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENTS

18.21 REATA PHARMACEUTICALS, INC.

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENT

18.22 RETROTOPE INC.

18.22.1 COMPANY SNAPSHOT

18.22.2 PRODUCT PORTFOLIO

18.22.3 RECENT DEVELOPMENT

18.23 SANOFI

18.23.1 COMPANY SNAPSHOT

18.23.2 REVENUE ANALYSIS

18.23.3 PRODUCT PORTFOLIO

18.23.4 RECENT DEVELOPMENT

18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.

18.24.1 COMPANY SNAPSHOT

18.24.2 REVENUE ANALYSIS

18.24.3 PRODUCT PORTFOLIO

18.24.4 RECENT DEVELOPMENT

18.25 SUTTER HEALTH

18.25.1 COMPANY SNAPSHOT

18.25.2 PRODUCT PORTFOLIO

18.25.3 RECENT DEVELOPMENTS

18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.

18.26.1 COMPANY SNAPSHOT

18.26.2 REVENUE ANALYSIS

18.26.3 PRODUCT PORTFOLIO

18.26.4 RECENT DEVELOPMENT

18.27 VIATRIS INC.

18.27.1 COMPANY SNAPSHOT

18.27.2 REVENUE ANALYSIS

18.27.3 PRODUCT PORTFOLIO

18.27.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表のリスト

TABLE 1  ASIA PACIFIC ATAXIA MARKET: PIPELINE ANALYSIS

TABLE 2  ASIA PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3  ASIA PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4  ASIA PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5  ASIA PACIFIC ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6  ASIA PACIFIC EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7  ASIA PACIFIC OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8  ASIA PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 9  ASIA PACIFIC TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 10  ASIA PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 11  ASIA PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 12  ASIA PACIFIC STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 13  ASIA PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 14  ASIA PACIFIC ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 15  ASIA PACIFIC NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 16  ASIA PACIFIC ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 17  ASIA PACIFIC ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 18  ASIA PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 19  ASIA PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 20  ASIA PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 21  ASIA PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 22  ASIA PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23  ASIA PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 24  ASIA PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 25  ASIA PACIFIC ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 26  ASIA PACIFIC SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27  ASIA PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 28  ASIA PACIFIC LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29  ASIA PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 30  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31  ASIA PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 32  ASIA PACIFIC ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33  ASIA PACIFIC PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35  ASIA PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 36  ASIA PACIFIC ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37  ASIA PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 38  ASIA PACIFIC CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39  ASIA PACIFIC GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40  ASIA PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41  ASIA PACIFIC HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42  ASIA PACIFIC CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43  ASIA PACIFIC HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 45  ASIA PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 46  ASIA PACIFIC DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 47  ASIA PACIFIC RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 48  ASIA PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 49  ASIA PACIFIC OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 50  ASIA-PACIFIC ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 51  ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 52  ASIA-PACIFIC SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 53  ASIA-PACIFIC ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 54  ASIA-PACIFIC TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 55  ASIA-PACIFIC PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 56  ASIA-PACIFIC STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 57  ASIA-PACIFIC GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 58  ASIA-PACIFIC ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 59  ASIA-PACIFIC NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 60  ASIA-PACIFIC ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 61  ASIA-PACIFIC ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 62  ASIA-PACIFIC ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 63  ASIA-PACIFIC SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 64  ASIA-PACIFIC LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 65  ASIA-PACIFIC SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 66  ASIA-PACIFIC DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 67  ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 68  ASIA-PACIFIC IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 69  ASIA-PACIFIC SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 70  ASIA-PACIFIC LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 71  ASIA-PACIFIC ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 72  ASIA-PACIFIC ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 73  ASIA-PACIFIC ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 74  ASIA-PACIFIC ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 75  ASIA-PACIFIC ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 76  ASIA-PACIFIC RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 77  CHINA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 78  CHINA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 79  CHINA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 80  CHINA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 81  CHINA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 82  CHINA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 83  CHINA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 84  CHINA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 85  CHINA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 86  CHINA ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 87  CHINA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 88  CHINA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 89  CHINA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 90  CHINA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 91  CHINA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 92  CHINA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 93  CHINA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 94  CHINA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 95  CHINA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 96  CHINA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 97  CHINA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 98  CHINA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 99  CHINA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 100  CHINA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101  CHINA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102  CHINA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103  JAPAN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 104  JAPAN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 105  JAPAN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 106  JAPAN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 107  JAPAN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 108  JAPAN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 109  JAPAN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 110  JAPAN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 111  JAPAN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 112  JAPAN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 113  JAPAN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 114  JAPAN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 115  JAPAN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 116  JAPAN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 117  JAPAN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 118  JAPAN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 119  JAPAN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 120  JAPAN IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 121  JAPAN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 122  JAPAN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 123  JAPAN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 124  JAPAN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 125  JAPAN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 126  JAPAN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 127  JAPAN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 128  JAPAN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 129  INDIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 130  INDIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 131  INDIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 132  INDIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 133  INDIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 134  INDIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 135  INDIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 136  INDIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 137  INDIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 138  INDIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 139  INDIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 140  INDIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 141  INDIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 142  INDIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 143  INDIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 144  INDIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 145  INDIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 146  INDIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 147  INDIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 148  INDIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 149  INDIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 150  INDIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 151  INDIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 152  INDIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 153  INDIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 154  INDIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 155  SOUTH KOREA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 156  SOUTH KOREA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 157  SOUTH KOREA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 158  SOUTH KOREA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 159  SOUTH KOREA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 160  SOUTH KOREA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 161  SOUTH KOREA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 162  SOUTH KOREA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 163  SOUTH KOREA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 164  SOUTH KOREA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 165  SOUTH KOREA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 166  SOUTH KOREA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 167  SOUTH KOREA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 168  SOUTH KOREA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 169  SOUTH KOREA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 170  SOUTH KOREA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 171  SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 172  SOUTH KOREA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 173  SOUTH KOREA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 174  SOUTH KOREA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 175  SOUTH KOREA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176  SOUTH KOREA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 177  SOUTH KOREA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 178  SOUTH KOREA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 179  SOUTH KOREA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 180  SOUTH KOREA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 181  AUSTRALIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 182  AUSTRALIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 183  AUSTRALIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 184  AUSTRALIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 185  AUSTRALIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 186  AUSTRALIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 187  AUSTRALIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 188  AUSTRALIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 189  AUSTRALIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 190  AUSTRALIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 191  AUSTRALIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 192  AUSTRALIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 193  AUSTRALIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 194  AUSTRALIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 195  AUSTRALIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 196  AUSTRALIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 197  AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 198  AUSTRALIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 199  AUSTRALIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 200  AUSTRALIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 201  AUSTRALIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 202  AUSTRALIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 203  AUSTRALIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 204  AUSTRALIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 205  AUSTRALIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 206  AUSTRALIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 207  SINGAPORE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 208  SINGAPORE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 209  SINGAPORE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 210  SINGAPORE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 211  SINGAPORE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 212  SINGAPORE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 213  SINGAPORE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 214  SINGAPORE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 215  SINGAPORE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 216  SINGAPORE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 217  SINGAPORE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 218  SINGAPORE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 219  SINGAPORE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 220  SINGAPORE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 221  SINGAPORE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 222  SINGAPORE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 223  SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 224  SINGAPORE IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 225  SINGAPORE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 226  SINGAPORE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 227  SINGAPORE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 228  SINGAPORE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 229  SINGAPORE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 230  SINGAPORE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 231  SINGAPORE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 232  SINGAPORE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 233  THAILAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 234  THAILAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 235  THAILAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 236  THAILAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 237  THAILAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 238  THAILAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 239  THAILAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 240  THAILAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 241  THAILAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 242  THAILAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 243  THAILAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 244  THAILAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 245  THAILAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 246  THAILAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 247  THAILAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 248  THAILAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 249  THAILAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 250  THAILAND IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 251  THAILAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 252  THAILAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 253  THAILAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 254  THAILAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 255  THAILAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 256  THAILAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 257  THAILAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 258  THAILAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 259  MALAYSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 260  MALAYSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 261  MALAYSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 262  MALAYSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 263  MALAYSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 264  MALAYSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 265  MALAYSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 266  MALAYSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 267  MALAYSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 268  MALAYSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 269  MALAYSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 270  MALAYSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 271  MALAYSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 272  MALAYSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 273  MALAYSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 274  MALAYSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 275  MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 276  MALAYSIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 277  MALAYSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 278  MALAYSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 279  MALAYSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 280  MALAYSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 281  MALAYSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 282  MALAYSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 283  MALAYSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 284  MALAYSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 285  INDONESIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 286  INDONESIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 287  INDONESIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 288  INDONESIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 289  INDONESIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 290  INDONESIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 291  INDONESIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 292  INDONESIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 293  INDONESIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 294  INDONESIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 295  INDONESIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 296  INDONESIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 297  INDONESIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 298  INDONESIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 299  INDONESIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 300  INDONESIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 301  INDONESIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 302  INDONESIA IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 303  INDONESIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 304  INDONESIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 305  INDONESIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 306  INDONESIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 307  INDONESIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 308  INDONESIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 309  INDONESIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 310  INDONESIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 311  PHILIPPINES ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 312  PHILIPPINES SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 313  PHILIPPINES ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 314  PHILIPPINES TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 315  PHILIPPINES PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 316  PHILIPPINES STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 317  PHILIPPINES GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 318  PHILIPPINES ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 319  PHILIPPINES NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 320  PHILIPPINES ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 321  PHILIPPINES ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 322  PHILIPPINES ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 323  PHILIPPINES SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 324  PHILIPPINES LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 325  PHILIPPINES SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 326  PHILIPPINES DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 327  PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 328  PHILIPPINES IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 329  PHILIPPINES SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 330  PHILIPPINES LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 331  PHILIPPINES ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 332  PHILIPPINES ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 333  PHILIPPINES ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 334  PHILIPPINES ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 335  PHILIPPINES ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 336  PHILIPPINES RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 337  VIETNAM ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 338  VIETNAM SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 339  VIETNAM ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 340  VIETNAM TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 341  VIETNAM PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 342  VIETNAM STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 343  VIETNAM GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 344  VIETNAM ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 345  VIETNAM NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 346  VIETNAM ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 347  VIETNAM ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 348  VIETNAM ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 349  VIETNAM SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 350  VIETNAM LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 351  VIETNAM SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 352  VIETNAM DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 353  VIETNAM IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)

TABLE 354  VIETNAM IMAGING TEST IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 355  VIETNAM SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 356  VIETNAM LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)

TABLE 357  VIETNAM ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 358  VIETNAM ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 359  VIETNAM ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)

TABLE 360  VIETNAM ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 361  VIETNAM ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 362  VIETNAM RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 363  RESTF OF ASIA-PACIFIC ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

図表一覧

FIGURE 1  ASIA PACIFIC ATAXIA MARKET: SEGMENTATION

FIGURE 2  ASIA PACIFIC ATAXIA MARKET: DATA TRIANGULATION

FIGURE 3  ASIA PACIFIC ATAXIA MARKET: DROC ANALYSIS

FIGURE 4  ASIA PACIFIC ATAXIA MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5  ASIA PACIFIC ATAXIA MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6  ASIA PACIFIC ATAXIA MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7  ASIA PACIFIC ATAXIA MARKET: DBMR MARKET POSITION GRID

FIGURE 8  ASIA PACIFIC ATAXIA MARKET: END USER COVERAGE GRID

FIGURE 9  ASIA PACIFIC ATAXIA MARKET: VENDOR SHARE ANALYSIS

FIGURE 10  ASIA PACIFIC ATAXIA MARKET: SEGMENTATION

FIGURE 11  RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE ASIA PACIFIC ATAXIA MARKET IN THE FORECAST PERIOD

FIGURE 12  SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ATAXIA MARKET IN 2022 & 2029

FIGURE 13  NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14  DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ATAXIA MARKET

FIGURE 15  ASIA PACIFIC ATAXIA MARKET: BY TYPE, 2021

FIGURE 16  ASIA PACIFIC ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)

FIGURE 17  ASIA PACIFIC ATAXIA MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 18  ASIA PACIFIC ATAXIA MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, 2021

FIGURE 20  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)

FIGURE 21  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 22  ASIA PACIFIC ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 23  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, 2021

FIGURE 24  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)

FIGURE 25  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 26  ASIA PACIFIC ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 27  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 28  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)

FIGURE 29  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 30  ASIA PACIFIC ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 31  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, 2021

FIGURE 32  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)

FIGURE 33  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)

FIGURE 34  ASIA PACIFIC ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 35  ASIA PACIFIC ATAXIA MARKET: BY END USER, 2021

FIGURE 36  ASIA PACIFIC ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)

FIGURE 37  ASIA PACIFIC ATAXIA MARKET: BY END USER, CAGR (2022-2029)

FIGURE 38  ASIA PACIFIC ATAXIA MARKET: BY END USER, LIFELINE CURVE

FIGURE 39  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 40  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)

FIGURE 41  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 42  ASIA PACIFIC ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43  ASIA-PACIFIC ATAXIA MARKET: SNAPSHOT (2021)

FIGURE 44  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021)

FIGURE 45  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2022 & 2029)

FIGURE 46  ASIA-PACIFIC ATAXIA MARKET: BY COUNTRY (2021 & 2029)

FIGURE 47  ASIA-PACIFIC ATAXIA MARKET: BY TYPE (2022-2029)

FIGURE 48  ASIA PACIFIC ATAXIA MARKET: COMPANY SHARE 2021 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

Asia-Pacific Ataxia Market is growing with a CAGR of 7.8% by 2029.
Asia-Pacific Ataxia Market is expected to reach USD 7,734.86 thousand by 2029.
The difficulty in diagnosing the disease and lack of genetic testing facilities in some of the developing countries will impede the growth rate of the ataxia market.
The major players operating in the Asia-Pacific ataxia market are Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Reata Pharmaceuticals, Inc., Biohaven Pharmaceuticals, among others.